Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13600
Abstract: Sustained virologic response at posttreatment Week 12 (SVR12) is the widely accepted efficacy endpoint for direct‐acting antiviral agents. Those with hepatitis C virus (HCV) are presenting younger with milder liver disease, potentially reducing need for… read more here.
Keywords: response weeks; sustained virologic; virologic response; clinical trials ... See more keywords